Melanotan II and the dysplastic mole question — what the dermatology literature shows

The relationship between Melanotan II and pigmented skin lesions is one of the more important and, for a long time, under-discussed safety questions around the compound. The dermatology literature has been building a case report record for over fifteen years. The picture that emerges is not definitive — the confounds are real and significant, and establishing causation from case reports is methodologically fraught — but it is concerning in ways that warrant serious attention from anyone who has used or is considering using MT-II.

To understand the concern, you need to start with what melanocortin receptor activation actually does in the skin. MC1R is expressed on melanocytes, and its activation by alpha-MSH or synthetic agonists drives two related but distinct processes. The first is melanogenesis: the synthesis of eumelanin pigment, which is the intended tanning effect. The second is melanocyte proliferation: MC1R signaling has mitogenic properties, meaning it can stimulate melanocyte cell division. Normally, melanocyte proliferation is tightly regulated — the number of melanocytes in any skin area stays relatively constant, controlled by growth factor balance and contact inhibition. Sustained, high-level MC1R activation can push against that regulation. In healthy melanocytes with intact tumor suppressor function, this is likely a minor and reversible effect. In melanocytes that already carry dysplastic changes — pre-malignant alterations in their DNA that compromise their growth regulation — the additional mitogenic stimulus from MC1R activation is a different matter.

The early case reports began appearing in the mid-2000s in British and Australian dermatology journals, reflecting the geographies where MT-II use was most concentrated. The pattern was consistent across reports: patients presented with moles that had changed in appearance — darkening, enlarging, developing irregular borders — after beginning MT-II use. In some reports, patients noted new moles appearing in areas of skin that had previously been clear. Dermatoscopic examination of the lesions frequently showed atypical features. In several cases, excision and histopathology revealed dysplastic nevi — moles with abnormal cellular architecture that, while not yet malignant, represent an elevated risk for melanoma development. In a smaller number of cases, the histopathology showed changes more concerning than dysplasia.

The most serious cases in the literature involve melanoma diagnoses in MT-II users. A 2011 case report published in a British dermatology journal documented a young patient with no family history of melanoma who developed a melanoma following several months of MT-II use. The lesion had changed in appearance during the MT-II period. The authors were careful about causation: they noted that the patient had significant prior UV exposure and that the melanoma could have developed independently. But they also noted that the timeline was consistent with MC1R-driven melanocyte stimulation accelerating progression of a dysplastic precursor. A 2009 report described two patients in the UK with new or changed pigmented lesions following MT-II use, with histopathological findings of varying severity. Other reports from Australia, Germany, and Spain have followed similar patterns over the subsequent years.

It is worth being precise about what the case report literature can and cannot tell us. Case reports document individual occurrences. They cannot establish incidence rates, because the denominator — how many people are using MT-II overall — is unknown and unknowable given the unregulated nature of the supply chain. They cannot establish causation on their own, because the baseline rate of atypical mole changes in a young population that self-selects for body-modification practices and that is, by definition, exposing itself to UV light for the purpose of tanning is not a clean baseline. A person using MT-II to tan is typically also using UV — tanning beds or sun exposure — to catalyze the tanning effect, which is its own independent risk factor for melanocyte DNA damage.

But there is a plausible mechanism connecting MT-II to dysplastic progression, and that mechanism is not trivially dismissed. MC1R stimulation in skin cells that already carry mutations in BRAF, CDKN2A, or other melanoma driver genes — mutations that are present in many dysplastic nevi — creates a permissive environment for further proliferation. The compound does not need to cause the underlying mutation to accelerate what was already there. This is not a theoretical concern invented in the absence of evidence; it is the mechanism that animal models of pharmacological MC1R activation have consistently produced when dysplastic precursors are present, and it is consistent with the direction of the case report observations.

The dermatology community's response to this evidence has been consistent: anyone using MC1R agonists without medical oversight should have regular full-body skin examinations. This recommendation appears in the patient information for afamelanotide (Scenesse) as well — even for the approved pharmaceutical formulation. In the context of MT-II, where use is unmonitored, where doses are self-determined, where purity of the compound is uncertain, and where there is no physician following the patient's skin over time, that recommendation cannot be operationalized. You cannot do what the recommendation asks if no one knows you are using the compound.

There is also a timing issue that matters. Moles do not change overnight. Dysplastic progression is typically a process that unfolds over months to years. A person who uses MT-II for a few weeks, sees no obvious skin changes, and stops cannot draw conclusions from the absence of immediate observable harm. The changes that warrant concern may develop on a longer timeline and may be noticed — or not noticed — only incidentally, or only by a trained dermoscopist during a systematic full-body examination. The community practice of performing self-checks and monitoring for visible changes is directionally reasonable but is not equivalent to clinical follow-up.

The honest summary of what the dermatology literature shows is this: there is a biologically plausible mechanism by which MC1R stimulation could accelerate dysplastic mole progression in predisposed individuals; there are multiple case reports consistent with this mechanism occurring in MT-II users; there is no randomized controlled trial data on MT-II in humans from which any reliable safety conclusions about skin cancer risk can be drawn; and the compound is not approved for human use anywhere, meaning any use occurs without the safety monitoring infrastructure that would generate such data. The parallel situation for afamelanotide — the approved pharmaceutical — exists under controlled conditions with dermatological monitoring, which is precisely why the risk can be managed for EPP patients.

The buyer in the gray market exists in a different situation entirely. They do not have a prescribing physician monitoring their skin. They are using a compound of uncertain purity and composition. They have no long-term safety data to consult. What they have is forum discussions, community-synthesized dosing protocols, and a set of case reports in the medical literature that most of them have never read. The fact that many people who use MT-II never notice obvious skin changes does not mean no harm occurred — it may mean the harm is occurring on a timeline that extends beyond the observation window of any individual user, or that the harm is subclinical and detectable only by trained examination, or that the harm occurs selectively in people with pre-existing dysplastic lesions who are, by definition, the population who can least afford additional melanocyte stimulation.

The question of whether MT-II causes melanoma cannot currently be answered. The question of whether it might accelerate pre-existing dysplastic progression through a well-characterized mechanism, in the absence of any counterbalancing safety data, in an uncontrolled setting with no monitoring — that question has a different answer.